Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer considering major acquisitions

Pfizer considering major acquisitions

8th March 2006

Pfizer is looking to buy pharmaceutical and biotechnology companies worth between $1 billion and $4 billion, Reuters has reported.

Speaking to the Boston Cowen & Co Health care conference, vice chairman David Sherdlarz said that the company was aiming to purchase firms with a wide range of products in different stages of development.

He pointed to the acquisition of biotech firm Vicuron Pharmaceuticals last year as an example of where the company was headed. Vicuron currently focuses on anti-infective development.

However, Pfizer’s tendency to take full control of the companies it acquires may need to be loosened, Mr Sherdlarz said. Options such as allowing firms to operate independently with Pfizer as the main shareholder may be on the table.

Mr Sherdlarz said that the firm would need to be more open to “those types of opportunities” but commented that “our history is going to rub against that”.

Marketwatch reported that at the same conference the firm announced it wants to use its current vast manufacturing ability to enter into the generic biologics market ? a sector where few will have the capital to compete.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.